1)
Mega-blockbuster- "Godzilla-is-a small bug"- drug
While not
released yet, Acomplia, s
likely to turn the pharmaceutical world on its ear. It works
against both obesity and smoking.
This is
probably the best example of a “lifestyle” drug I have seen to
date. This will be a huge issue and the drug likely to be a
MEGA-BLOCKBUSTER (but one for which members would likely pay
cash).
From a large
employer vantage there is little risk. The advantage is that
most plans that do not cover smoking cessation ALSO do not cover
weight loss drugs. These clients would not be adversely effected
by the release of this drug if it is properly coded by First
Data Bank. (The drug should also be listed in the logic of BOTH
classes of drug: smoking and obesity.)
It is simply
“not a covered benefit”. Clients may wish to state this
explicitly in their SPD benefit explanations to employees when
the drug is finally released..
For those
clients who DO offer either a smoking or obesity benefit we
might have to use a stepped approach. Criteria could
“grandfather” anyone who has a past claim for a prescription
smoking cessation drug, . If used for smoking then a time limit
would be in order. If for weight reduction then some BMA
calculation logic could be applied.
http://www.fitforsummer.com/acomplia1.htm
2)
Dangerous drugs precipitate "Sudden Cardiac Death"…
Erythromycin,
especially combined with some other cardiac medications,
resulted in more deaths that those who took neither. This
interested me because of my past experience as the drug
interaction editor for Medispan.. The erythromycins have been
implicated in many cardiac rhythym problem in the past so it is
not shocking to me. Read on to find out the other culprit
drugs….
http://www.medscape.com/viewarticle/488921?src=mp
or
http://www.newsday.com/news/health/wire/sns-ap-antibiotic-deaths,0,7134711.story?coll=sns-ap-health-headlines
3) Feeling
restless?
Requip, an
anti Parkinson's drug, has been tested for "restless leg
syndrome".
Have you ever
been in a meeting with someone who can’t stop bouncing his leg
or legs up and down? He could be suffering from “Restless Leg
Syndrome”. It definitely burns calories but at the expense of
social stigma. If this is approved it would be the first for
RLS. Not a potential blockbuster…but interesting.
http://yahoo.reuters.com/financeQuoteCompanyNewsArticle.jhtml?duid=mtfh96716_2004-09-06_13-59-40_l06347324_newsml
4) Another
one bites the dust…
FDA does NOT
approve the anticlotting drug, Exanta….Cardiovascular risk and
that of liver failure are too high. Back to the drawing boards….
Note: the drug company will have to recoup the cost of the
development of this drug somewhere…. They need the freedom to
price accordingly or the US will take the place of Europe as an
area where new drugs USED to come from. (IMHO…. see last article
foe the translation(
http://www.reuters.com/newsArticle.jhtml?type=healthNews&storyID=6208988